Glenmark Pharmaceuticals Reports Decline in Profitability and Rising Interest Expenses in June 2025 Results
Glenmark Pharmaceuticals has announced its financial results for the quarter ending June 2025, showing a decline in both Profit After Tax and Profit Before Tax compared to previous averages. Additionally, interest expenses have risen, indicating potential increases in borrowings and challenges in financial flexibility. The company's score has also been revised significantly.
Glenmark Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, revealing notable trends within its performance metrics. The company's Profit After Tax (PAT) for the quarter stands at Rs 205.71 crore, reflecting a significant shift compared to the average PAT of Rs 312.99 crore from the previous four quarters, indicating challenges in maintaining profitability. Additionally, the Profit Before Tax (PBT) has also shown a decline, recorded at Rs 392.37 crore, which is lower than the average PBT of Rs 414.57 crore over the same period.On a different note, Glenmark has experienced an adjustment in its interest expenses, with the latest six-month figure reaching Rs 124.94 crore, which marks an increase compared to the previous half-year period. This rise in interest costs suggests a potential increase in borrowings, which could impact the company's financial flexibility moving forward.
Overall, Glenmark Pharmaceuticals has undergone evaluation changes in its financial standing, as reflected in its score, which has seen a revision from 11 to 5 over the last three months.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Activity
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Most Read
